Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
111,111,111
-
Number of holders
-
301
-
Total 13F shares, excl. options
-
77,530,211
-
Shares change
-
-124,038
-
Total reported value, excl. options
-
$9,007,824,387
-
Value change
-
-$79,435,404
-
Put/Call ratio
-
140%
-
Number of buys
-
135
-
Number of sells
-
-189
-
Price
-
$116.17
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q3 2021
415 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q3 2021.
NovoCure Ltd - Common Stock (NVCR) has 301 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 77,530,211 shares
of 111,111,111 outstanding shares and own 69.78% of the company stock.
Largest 10 shareholders include Capital World Investors (12,620,500 shares), Capital International Investors (10,556,816 shares), BAILLIE GIFFORD & CO (9,369,705 shares), FMR LLC (8,274,886 shares), VANGUARD GROUP INC (7,861,860 shares), BlackRock Inc. (6,723,680 shares), STATE STREET CORP (2,203,547 shares), PRICE T ROWE ASSOCIATES INC /MD/ (1,432,467 shares), CREDIT SUISSE AG/ (1,384,351 shares), and GEODE CAPITAL MANAGEMENT, LLC (1,230,466 shares).
This table shows the top 301 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.